McGill University, Université de Montreal, Yeda Research and Development Co. Ltd. and Yissum Research Development Co. have jointly developed anisomycin analogues reported to be useful for the treatment of giardiasis, leishmaniasis, toxoplasmosis and trypanosomiasis.
